Dr. Reddy's Laboratories Limited
HealthcareNYSE:RDY · New York Stock Exchange
-$0.06 today
Vol 1.01M · Avg 2.44M
Management
Put operating results in leadership context
Review returns on capital, executive background, insider transactions, and growth quality to judge whether management is compounding value well.
Return Metrics
ROE, ROIC & ROA over time
ROE
12.2%
avg 99.0%
ROIC
8.1%
avg 70.9%
ROA
7.9%
avg 65.9%
Analysis
ROE is currently the strongest return metric at 12.2% versus its period average of 99.0%. 1 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Tenure | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|---|
Gunupati Venkateswara Prasad | Co-Chairman, MD & Member of Management Council | $1.65M | — | 66 | $96.10M | 11.54% |
Kallam Satish Reddy | Chairman of the Board & Member of the Management Council | $1.05M | — | 59 | $75.63M | 9.08% |
Sanjay Sharma | Executive VP, COO & Member of Management Council | — | — | 58 | $0.00 | <0.01% |
Sushrut Kulkarni | Global Head of Integrated Product Development Organisation & Member of the Management Council | — | — | 55 | $70.00 | <0.01% |
Bhethanabottla S. Phanimitra | Chief Digital & Information Officer and Member of the Management Council | — | — | 46 | $8,712.00 | <0.01% |
Deepak Sapra | Global Head of Pharmaceutical Services and Active Ingredients & Member of Management Council | — | — | 51 | $75,624.00 | <0.01% |
Erez Israeli | Chief Executive Officer & Member of the Management Council | — | — | 58 | $0.00 | <0.01% |
Krishna K. Venkatesh B.Pharma | Global Head of IPDO, Integrated Product Development & Member of the Management Council | — | — | 53 | $0.00 | <0.01% |
Mannam Venkatanarasimham | Chief Financial Officer & Member of the Management Council | — | — | 56 | $61,245.00 | <0.01% |
Motupalli Venkata Ramana | CEO of Global Generics & Member of Management Council | — | — | 57 | $68,230.00 | <0.01% |
Patrick Aghanian | Head of Consumer Health Organization & Member of Management Council | — | — | 61 | $8,450.00 | <0.01% |
Insider Trading
SEC Form 4 transactions — last 12 months
No insider transactions in the last 12 months.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | +5.9% | -3.5% (13yr)1 analysts |
| Revenue | N/A | N/A | +10.0% | +8.0% (13yr)11 analysts |
| Net Income | N/A | N/A | +6.1% | +9.0% (13yr)11 analysts |
| EBIT | N/A | N/A | +11.9% | +8.8% (13yr)11 analysts |
Analysis
Recent growth has been strongest in EBIT at +11.9% over three years. Forward estimates point to Net Income at +9.0% (13yr), giving you a quick check on whether expectations are accelerating or cooling.
Competitors
Peer companies in the same sector
Revolution Medicines, Inc.
NASDAQ:RVMD
$32.71B
Viatris Inc.
NASDAQ:VTRS
$19.19B
Neurocrine Biosciences, Inc.
NASDAQ:NBIX
$16.06B
Solventum Corporation
NYSE:SOLV
$13.66B
Exelixis, Inc.
NASDAQ:EXEL
$13.35B
Elanco Animal Health Incorporated
NYSE:ELAN
$12.07B
Revvity, Inc.
NYSE:RVTY
$11.12B
BioMarin Pharmaceutical Inc.
NASDAQ:BMRN
$10.81B
Encompass Health Corporation
NYSE:EHC
$10.07B
The Ensign Group, Inc.
NASDAQ:ENSG
$8.73B
Who manages RDY?
Dr. Reddy's Laboratories Limited (RDY) lists 11 active executives. The top listed executive is Sanjay Sharma, Executive VP, COO & Member of Management Council.
Are RDY insiders buying or selling?
Recent insider activity shows net buying of $0.00.
Explore More
Continue the stock analysis
Jump to another research area for this company.